Temporal evolution of breast cancer brain metastases treatments and outcomes
Michele Bottosso(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Fabio Girardi(London School of Hygiene & Tropical Medicine), Grazia Maria Vernaci(University of Padua), Christian Zurlo(Istituto Oncologico Veneto), Alessandro Parisi(Marche Polytechnic University), Jean-Marc Ferrero(Centre Antoine Lacassagne), Séverine Guiu(Inserm), Vittoria Aldegheri(Istituto Oncologico Veneto), Caroline Bailleux(Centre Antoine Lacassagne), William Jacot(Inserm), Maria Cristina Guarascio(University of Padua), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Maria Vittoria Dieci(University of Padua), Anna Chiara Cattelan(Istituto Oncologico Veneto), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua)
Cited by 6
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346